Hematological Disorders

📚 03 Neonatology • 🎯 30 High-Yield MCQs • Nelson 22nd Edition Standard

Fetal & Neonatal Hematopoiesis

  • Embryonic & Fetal Hematopoietic Shifts: ((NHEM001)): Primitive erythropoiesis begins in the yolk sac (producing cells with limited lineage potential), followed by early progenitors in the aortogonadomesonephron region colonizing the fetal liver. The fetal liver becomes the predominant site of hematopoiesis (producing all major lineages, peaking at 5-6 months gestation) before bone marrow hematopoiesis is fully established (marrow begins around 8 weeks but takes several weeks to dominate).
  • Hypoxia-Inducible Factor (HIF) Regulation: ((NHEM002)): Erythropoietin production is regulated by the HIF complex. The HIF-α subunit is highly oxygen-sensitive (hydrolyzed and degraded by prolyl hydroxylase in normoxia; stabilized and translocated during hypoxia), while the HIF-β subunit is constitutively expressed and oxygen-insensitive.
  • Myeloid Lineage Differentiation: ((NHEM003)): Pluripotent hematopoietic stem cells differentiate into common myeloid progenitors which give rise to erythrocytes, granulocytes, monocytes, and megakaryocytes. Megakaryocytes develop through the CFU-MK (colony-forming unit–megakaryocyte) pathway before fragmenting into platelets.

Neonatal Coagulation & Anticoagulant Profile

  • Physiologic Anticoagulant Balance: ((NHEM004)): Neonates have naturally decreased levels of antithrombin III, Protein C, and Protein S, but are protected from spontaneous thrombosis by a compensatory increase in alpha2-macroglobulin (a broad-spectrum protease inhibitor regulating thrombin).
  • Target Specificity of Anticoagulants: ((NHEM005)):
  • Antithrombin III: targets activated factors IIa (thrombin), IXa, Xa, and XIa.
  • Protein C: (with cofactor Protein S) specifically inactivates coagulation cofactors Va and VIIIa.
  • Acquired Coagulopathy (Liver Disease vs. DIC): ((NHEM013)): Neonatal hepatic dysfunction causes global reduction of clotting factors and fibrinogen resulting in prolonged PT and APTT with decreased fibrinogen and normal platelet counts (differentiating it from DIC which features marked thrombocytopenia and consumptive coagulopathy).

Neonatal Thrombosis & Vascular Access Complications

  • Peripheral Vasospasm Management: ((NHEM014)): Persistent peripheral vasospasm from umbilical arterial catheters unresponsive to 15 minutes of contralateral limb warming (with palpable pulses and no necrosis) requires local application of 2% nitroglycerin ointment (vasodilator) before considering catheter removal.
  • Aortic vs. Renal Thrombosis: ((((NHEM015)) · ((HEM025)))): - Renal vein thrombosis (RVT) with IVC extension or renal failure requires *initial thrombolysis with rt-PA followed by anticoagulation* (uncomplicated RVT uses anticoagulation alone).
  • Aortic thrombosis: (associated with umbilical arterial catheters) presents with diminished femoral pulses, normal upper limb pulses, and systemic hypertension due to renal hypoperfusion, mimicking coarctation.
  • Low-Molecular-Weight Heparin (LMWH) Dosing: ((NHEM016)): Therapeutic LMWH dosing in neonates varies by maturity: preterm infants $\le$32 weeks gestation require 1.5 mg/kg subcutaneously every 12 hours, whereas infants >32 weeks require 2 mg/kg subcutaneously every 12 hours.

Neonatal Thrombocytopenia & Platelet Disorders

  • Maternal ITP-Induced Thrombocytopenia: ((NHEM006)): Platelet nadir occurs between days 2–5 of life (requiring repeat counts even if mild at birth). Cranial imaging is mandatory if platelet count is $<50,000/\mu L$ to screen for intracranial hemorrhage. IVIG is indicated only when platelets fall $<30,000/\mu L$ (not $<50,000/\mu L$, making that threshold incorrect).
  • Neonatal Alloimmune Thrombocytopenia (NAIT): ((NHEM017)): Initial management for a clinically stable neonate with petechiae and severe thrombocytopenia is random donor platelet transfusion (transfusion threshold $<30 \times 10^9/L$). Antigen-negative maternal platelets or HPA-matched units should be arranged concurrently.
  • Inherited Platelet Disorders: ((((NHEM007)) · ((HEM018)))):
  • Bernard-Soulier Syndrome: : Features macrothrombocytopenia (large platelets, low count) and defective aggregation with ristocetin that does not correct with normal plasma (GPIb receptor defect).
  • Management Rule: : Platelet transfusions in congenital platelet function defects (Bernard-Soulier, Glanzmann thrombasthenia) must be restricted exclusively to life-threatening bleeding to prevent alloimmunization and refractoriness against platelet glycoproteins (GPIb, GPIIb/IIIa). Desmopressin is contraindicated in neonates due to risk of hyponatremia and seizures.

Fetal Anemia, Hemoglobinopathies & Transfusion Protocols

  • Kleihauer-Betke Test Limitation: ((NHEM008)): Accuracy is compromised when the mother has elevated HbF (e.g., sickle cell disease, $\beta$-thalassemia, HPFH), as maternal RBCs retain stain, causing an erroneous overestimation of fetomaternal hemorrhage.
  • Hemoglobin Composition at Birth: ((NHEM009)): Neonatal hemoglobin contains predominantly alpha and gamma chains ($\text{HbF}, \alpha_2\gamma_2$), increasing beta chains near term ($\text{HbA}, \alpha_2\beta_2$), and trace delta chains ($\text{HbA}_2, \alpha_2\delta_2$), with complete absence of embryonic chains (epsilon, zeta).
  • Globin Switch & $\beta$-Thalassemia Timing: ((((NHEM022)) · ((HEM030)))): Clinical features of $\beta$-thalassemia major manifest around 12 weeks of age (~3 months), driven by the developmental hemoglobin switch governed by epigenetic suppression of $\gamma$-globin expression and simultaneous induction of $\beta$-globin gene transcription as HbF levels naturally decline.
  • Twin-to-Twin Transfusion Syndrome (TTTS): ((NHEM020)): Diagnostic criteria strictly require oligohydramnios (deepest vertical pocket $<2\text{ cm}$) in the donor twin and polyhydramnios (deepest vertical pocket $>8\text{ cm}$) in the recipient twin specifically in the absence of other etiologies for fluid discordance.
  • $\alpha$-Thalassemia Major Management: ((NHEM021)): Antenatally diagnosed severe fetal anemia with hydrops requires serial intrauterine packed red blood cell transfusions to prolong gestation, followed by postnatal transfusion support.
  • Neonatal RBC Transfusion Risks & CMV Prevention: ((((NHEM011)) · ((HEM019)))): - Multiple transfusions correlate with bronchopulmonary dysplasia, necrotizing enterocolitis, and retinopathy of prematurity (but not PPHN). - To prevent transfusion-transmitted CMV in preterm infants ($<1250\text{ g}$ from CMV-seronegative mothers), leukocyte-reduced packed RBCs are preferred over relying purely on CMV-seronegative donor blood.

Polycythemia & Hemolytic Disorders

  • Partial Exchange Transfusion Formula: ((NHEM024)): $$\text{Exchange Volume} = \frac{(\text{Observed Hct} - \text{Desired Hct}) \times \text{Blood Volume (mL/kg)} \times \text{Weight (kg)}}{\text{Observed Hct}}$$
  • Gestational-Age Specific RBC Indices: ((NHEM026)): Preterm infants (e.g., 30 weeks) normally exhibit higher MCV and MCH values compared to term norms; evaluating preterm indices against term standards falsely suggests relative macrocytosis and hyperchromia.
  • Rh Isoimmunization Management: ((NHEM027)): Middle cerebral artery peak systolic velocity (MCA-PSV) crossing $>1.5\text{ multiples of the median (MoM)}$ indicates moderate-to-severe fetal anemia and mandates cordocentesis for direct Hb assessment and possible intrauterine transfusion (replacing amniocentesis $\Delta\text{OD}_{450}$).
  • G6PD Deficiency & Oxidative Hemolysis: ((((NHEM028)) · ((HEM029)))): - Heinz bodies and bite cells characterize oxidant-induced hemolysis. - Superoxide radicals are converted to hydrogen peroxide by CuZn superoxide dismutase (SOD1). - Therapeutic prevention of hyperbilirubinemia utilizes tin-mesoporphyrin to inhibit heme oxygenase activity and suppress heme catabolism.

Immunology & Innate Immunity

  • Innate Lymphoid Cell (ILC) Plasticity: ((NHEM010)): ILCs lack antigen-specific receptors and are not fixed terminally; they exhibit functional plasticity, altering phenotype and cytokine profile in response to environmental and pathogenic signals.